Published in Clin Vaccine Immunol on July 17, 2013
Skin permeabilization for transdermal drug delivery: recent advances and future prospects. Expert Opin Drug Deliv (2014) 1.15
The success of microneedle-mediated vaccine delivery into skin. Hum Vaccin Immunother (2016) 0.83
Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice. Viruses (2015) 0.79
Cutaneous immunization: an evolving paradigm in influenza vaccines. Expert Opin Drug Deliv (2014) 0.77
Yeast Surface-Displayed H5N1 Avian Influenza Vaccines. J Immunol Res (2016) 0.75
Preparing for the next pandemic. N Engl J Med (2005) 4.65
Keratinocytes as initiators of inflammation. Lancet (1991) 3.68
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis (2008) 3.05
Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS Curr (2010) 2.77
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev (2012) 2.65
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine (2007) 2.31
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine (2005) 1.80
Why aging T cells fail: implications for vaccination. Immunity (2006) 1.78
Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol (2006) 1.68
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol (2011) 1.61
Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release (2012) 1.49
Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol (2005) 1.48
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine (2008) 1.31
Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol (2009) 1.28
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine (2009) 1.16
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep (2012) 1.14
A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine (2004) 1.09
Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release (2010) 1.05
Novel vaccines against influenza viruses. Virus Res (2011) 1.04
Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin (2010) 1.03
Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res (2010) 1.03
Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum Vaccin (2011) 1.02
Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol (2010) 1.01
Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis (2011) 1.01
Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech (2010) 0.98
Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J Biomech (2004) 0.96
Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol (2011) 0.94
Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release (2011) 0.93
Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol (2011) 0.90
Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther (2011) 0.84
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Gain-of-function experiments on H7N9. Science (2013) 3.67
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci U S A (2003) 2.82
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Coated microneedles for transdermal delivery. J Control Release (2006) 2.66
Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev (2012) 2.65
Effect of microneedle design on pain in human volunteers. Clin J Pain (2008) 2.48
Dissolving microneedles for transdermal drug delivery. Biomaterials (2008) 2.47
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release (2005) 2.19
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Transdermal delivery of insulin using microneedles in vivo. Pharm Res (2004) 2.07
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Mechanism of intracellular delivery by acoustic cavitation. Ultrasound Med Biol (2006) 2.02
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. J Biomech (2004) 1.91
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Micro-scale devices for transdermal drug delivery. Int J Pharm (2008) 1.81
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A (2008) 1.77
Polymer microneedles for controlled-release drug delivery. Pharm Res (2006) 1.72
Coating formulations for microneedles. Pharm Res (2007) 1.63
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Precise microinjection into skin using hollow microneedles. J Invest Dermatol (2006) 1.51
Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater (2008) 1.49
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Mechanism of fluid infusion during microneedle insertion and retraction. J Control Release (2006) 1.46
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One (2011) 1.44
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
Measurement and correlation of acoustic cavitation with cellular bioeffects. Ultrasound Med Biol (2006) 1.43
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol (2004) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Physical parameters influencing optimization of ultrasound-mediated DNA transfection. Ultrasound Med Biol (2004) 1.37
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat Nanotechnol (2010) 1.36
Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng (2005) 1.35
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine (2006) 1.33
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
Tapered conical polymer microneedles fabricated using an integrated lens technique for transdermal drug delivery. IEEE Trans Biomed Eng (2007) 1.30
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis (2011) 1.24
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A (2010) 1.22
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release (2011) 1.21
Inhibition of influenza infection by glutathione. Free Radic Biol Med (2003) 1.20
Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res (2010) 1.20
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol (2003) 1.20
Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther (2009) 1.19
TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci U S A (2002) 1.19
Bioeffects caused by changes in acoustic cavitation bubble density and cell concentration: a unified explanation based on cell-to-bubble ratio and blast radius. Ultrasound Med Biol (2003) 1.19
A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18
Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A (2009) 1.18
Minimally invasive extraction of dermal interstitial fluid for glucose monitoring using microneedles. Diabetes Technol Ther (2005) 1.17